Enliven Therapeutics (NASDAQ:ELVN) Rating Reiterated by HC Wainwright

Enliven Therapeutics (NASDAQ:ELVN)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $37.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 38.27% from the stock’s current price.

Several other research analysts have also weighed in on the company. Baird R W upgraded Enliven Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Robert W. Baird assumed coverage on Enliven Therapeutics in a research note on Tuesday, June 11th. They set an “outperform” rating and a $32.00 target price for the company.

Enliven Therapeutics Stock Up 4.8 %

ELVN stock traded up $1.22 during trading on Tuesday, hitting $26.76. 168,941 shares of the company’s stock traded hands, compared to its average volume of 253,850. The business has a fifty day simple moving average of $23.14 and a two-hundred day simple moving average of $21.71. The firm has a market capitalization of $1.26 billion, a P/E ratio of -13.79 and a beta of 1.09. Enliven Therapeutics has a 1 year low of $9.80 and a 1 year high of $27.67.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. On average, equities research analysts predict that Enliven Therapeutics will post -1.98 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Joseph P. Lyssikatos sold 3,099 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $27.56, for a total value of $85,408.44. Following the transaction, the insider now directly owns 1,089,936 shares in the company, valued at approximately $30,038,636.16. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $24.92, for a total value of $299,040.00. Following the completion of the transaction, the chief executive officer now owns 1,063,525 shares in the company, valued at approximately $26,503,043. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Joseph P. Lyssikatos sold 3,099 shares of Enliven Therapeutics stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $27.56, for a total value of $85,408.44. Following the completion of the transaction, the insider now owns 1,089,936 shares of the company’s stock, valued at approximately $30,038,636.16. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 119,555 shares of company stock worth $2,972,270. 29.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC raised its stake in Enliven Therapeutics by 74.8% during the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after acquiring an additional 305,397 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Enliven Therapeutics by 49.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock worth $2,667,000 after acquiring an additional 37,632 shares during the last quarter. First Turn Management LLC purchased a new stake in Enliven Therapeutics in the 2nd quarter worth about $9,657,000. Nicholas Investment Partners LP purchased a new stake in shares of Enliven Therapeutics in the second quarter worth approximately $1,310,000. Finally, Rhumbline Advisers boosted its stake in shares of Enliven Therapeutics by 29.9% during the 2nd quarter. Rhumbline Advisers now owns 49,627 shares of the company’s stock valued at $1,160,000 after buying an additional 11,420 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.